JPWO2021089678A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021089678A5
JPWO2021089678A5 JP2022521146A JP2022521146A JPWO2021089678A5 JP WO2021089678 A5 JPWO2021089678 A5 JP WO2021089678A5 JP 2022521146 A JP2022521146 A JP 2022521146A JP 2022521146 A JP2022521146 A JP 2022521146A JP WO2021089678 A5 JPWO2021089678 A5 JP WO2021089678A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glp
receptor agonist
composition according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500032A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081087 external-priority patent/WO2021089678A1/en
Publication of JP2023500032A publication Critical patent/JP2023500032A/ja
Publication of JPWO2021089678A5 publication Critical patent/JPWO2021089678A5/ja
Pending legal-status Critical Current

Links

JP2022521146A 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬 Pending JP2023500032A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP19207501.8 2019-11-06
EP20186623.3 2020-07-20
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (2)

Publication Number Publication Date
JP2023500032A JP2023500032A (ja) 2023-01-04
JPWO2021089678A5 true JPWO2021089678A5 (ru) 2023-11-14

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521146A Pending JP2023500032A (ja) 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬

Country Status (13)

Country Link
US (3) US20220280612A1 (ru)
EP (2) EP4054620B1 (ru)
JP (1) JP2023500032A (ru)
KR (1) KR20220110731A (ru)
CN (1) CN114728042A (ru)
AU (1) AU2020377469A1 (ru)
BR (1) BR112022007721A2 (ru)
CA (1) CA3154744A1 (ru)
IL (1) IL291876A (ru)
MX (1) MX2022004779A (ru)
RS (1) RS65780B1 (ru)
TW (1) TW202118509A (ru)
WO (1) WO2021089678A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022014862A2 (pt) * 2020-01-30 2022-10-11 Lilly Co Eli Usos terapêuticos de dulaglutida
JP2024500410A (ja) * 2020-12-16 2024-01-09 ザ チャイニーズ ユニバーシティー オブ ホンコン 老化脳機能低下を逆転する方法
CA3239054A1 (en) 2021-12-02 2023-06-08 Kobenhavns Universitet Peptide-drug conjugates for treatment of neurodegenerative diseases
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX345501B (es) * 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
US9764003B2 (en) * 2012-07-01 2017-09-19 Novo Nordisk A/S Use of long-acting GLP-1 peptides
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
PL3393496T3 (pl) * 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use

Similar Documents

Publication Publication Date Title
EP1750677B1 (en) Oral therapeutic compound delivery system
JP2009514874A5 (ru)
JP6353577B2 (ja) 組み合わせ組成物
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2007530620A (ja) メロキシカムを含む組成物
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
JP2019218379A5 (ru)
JP2020522560A5 (ru)
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
ES2604254T3 (es) Combinaciones de flurbiprofeno de liberación controlada y relajante muscular
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
IL272834B2 (en) Compositions of amantadine, their preparation, and methods of use
JP2016505050A5 (ru)
JP2019507786A5 (ru)
US20080138383A1 (en) Compositions and methods for treating seizures
JPWO2021089678A5 (ru)
JP5053665B2 (ja) 催眠用医薬組成物
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
KR20210021356A (ko) 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체
CA2368352A1 (en) Method for treating neurodegeneration
KR100379155B1 (ko) 새로운 진통제 조성물
EP4420660A1 (en) Use of edaravone in treatment of autism spectrum disorder